Frears J, Maizels J, FriedMan M
J Allergy Clin Immunol. 1976 May;57(5):391-5. doi: 10.1016/0091-6749(76)90053-1.
The value of betamethasone valerate by inhalation in the prophylactic therapy of severe childhood asthma has been established. To determine whether the efficacy of this drug is due to a local or a systemic action a double-blind crossover study of 28 days' treatment with oral betamethasone valerate and 28 days' treatment with inhaled steroid was carried out in 10 asthmatic children. Daily doses used were 1 mg orally and 800 mug by inhalation. Nine patients had fewer symptoms, higher peak expiratory flow rates, and a lower bronchodilator requirement on inhaled than on oral therapy. Exercise-induced bronchoconstriction was diminished on inhaled therapy. Five children requested early termination of the oral therapy period because of unacceptable symptoms. Nine parents stated a preference for the period of inhaled therapy. It is concluded that betamethasone valerate is highly effective by inhalation but that a comparable oral dose has no appreciable clinical effect.
吸入用戊酸倍他米松在儿童重症哮喘预防性治疗中的价值已得到证实。为确定该药物的疗效是源于局部作用还是全身作用，对10名哮喘儿童进行了一项双盲交叉研究，分别给予口服戊酸倍他米松治疗28天和吸入性类固醇治疗28天。口服日剂量为1毫克，吸入日剂量为800微克。9名患者在吸入治疗时症状较少，呼气峰值流速较高，支气管扩张剂需求量较低。吸入治疗可减轻运动诱发的支气管收缩。5名儿童因出现无法耐受的症状而要求提前终止口服治疗期。9名家长表示更喜欢吸入治疗期。结论是，吸入用戊酸倍他米松非常有效，但同等口服剂量没有明显的临床效果。
